<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p66" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_66{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_66{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_66{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_66{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_66{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_66{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_66{left:238px;bottom:1038px;letter-spacing:-0.01px;}
#t8_66{left:238px;bottom:1018px;letter-spacing:-0.01px;}
#t9_66{left:238px;bottom:999px;letter-spacing:-0.01px;}
#ta_66{left:238px;bottom:979px;letter-spacing:-0.01px;}
#tb_66{left:238px;bottom:960px;letter-spacing:-0.01px;}
#tc_66{left:238px;bottom:940px;letter-spacing:-0.01px;}
#td_66{left:238px;bottom:867px;letter-spacing:-0.01px;}
#te_66{left:238px;bottom:847px;letter-spacing:-0.01px;}
#tf_66{left:238px;bottom:828px;letter-spacing:-0.01px;}
#tg_66{left:238px;bottom:793px;letter-spacing:-0.01px;}
#th_66{left:238px;bottom:774px;letter-spacing:-0.01px;}
#ti_66{left:238px;bottom:754px;letter-spacing:-0.01px;}
#tj_66{left:238px;bottom:735px;letter-spacing:-0.01px;}
#tk_66{left:238px;bottom:715px;letter-spacing:-0.01px;}
#tl_66{left:238px;bottom:696px;letter-spacing:-0.01px;}
#tm_66{left:521px;bottom:696px;letter-spacing:-0.01px;}
#tn_66{left:238px;bottom:677px;letter-spacing:-0.01px;}
#to_66{left:238px;bottom:657px;letter-spacing:-0.01px;}
#tp_66{left:238px;bottom:638px;letter-spacing:-0.01px;}
#tq_66{left:238px;bottom:618px;letter-spacing:-0.01px;}
#tr_66{left:238px;bottom:599px;letter-spacing:-0.01px;}
#ts_66{left:238px;bottom:525px;letter-spacing:-0.01px;}
#tt_66{left:238px;bottom:506px;letter-spacing:-0.01px;}
#tu_66{left:238px;bottom:486px;letter-spacing:-0.01px;}
#tv_66{left:238px;bottom:467px;letter-spacing:-0.01px;}
#tw_66{left:238px;bottom:447px;letter-spacing:-0.01px;}
#tx_66{left:238px;bottom:428px;letter-spacing:-0.01px;}
#ty_66{left:238px;bottom:409px;letter-spacing:-0.01px;}
#tz_66{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_66{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_66{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_66{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_66{font-size:13px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s4_66{font-size:11px;font-family:NotoSans-Regular_7j-_1;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts66" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

@font-face {
	font-family: NotoSans-Regular_7j-_1;
	src: url("fonts/NotoSans-Regular_7j-_1.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg66Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg66" style="-webkit-user-select: none;"><object width="908" height="1286" data="66/66.svg" type="image/svg+xml" id="pdf66" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_66" class="t s0_66">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_66" class="t s1_66">66 </span>
<span id="t3_66" class="t s2_66">Before starting radiotherapy, the pre-therapeutic tumor extent and cervical lymph node </span>
<span id="t4_66" class="t s2_66">involvement are documented via panendoscopy and CT or MR. Tumor size is a prognostic </span>
<span id="t5_66" class="t s2_66">factor, with local control and thus functional preservation being more favorable for total </span>
<span id="t6_66" class="t s2_66">volumes of less than 80 ml [217, 218]. The clinical target volume (CTV) for high-dose radiation </span>
<span id="t7_66" class="t s2_66">(dose levels see above) includes all clinically and imaging-based (CT/MR) macroscopically </span>
<span id="t8_66" class="t s2_66">detectable tumor locations (primary tumor and affected lymph nodes) with a safety margin of </span>
<span id="t9_66" class="t s2_66">5-10 mm. When contouring the CTVs for elective radiation (usually 45-54 Gy) of potentially </span>
<span id="ta_66" class="t s2_66">microscopically affected lymph node regions, one should follow the published consensus </span>
<span id="tb_66" class="t s2_66">guidelines [219, 220]. Typically, levels IIA, III and IV are included on both sides, and in cases of </span>
<span id="tc_66" class="t s2_66">clinical involvement of these groups, also IIb and V. </span>
<span id="td_66" class="t s2_66">Subglottic spread requires inclusion of Level VI, while clear involvement of the posterior </span>
<span id="te_66" class="t s2_66">oropharyngeal/hypopharyngeal wall also requires inclusion of the retropharyngeal lymph </span>
<span id="tf_66" class="t s2_66">nodes. </span>
<span id="tg_66" class="t s2_66">Some study groups also use a CTV with an intermediate dose (usually 60 Gy) for lymph node </span>
<span id="th_66" class="t s2_66">regions with borderline large lymph nodes or a greatly increased number of lymph nodes that </span>
<span id="ti_66" class="t s2_66">are visible on CT but are formally of normal size. The contouring of the organs at risk should </span>
<span id="tj_66" class="t s2_66">also be carried out according to published guidelines [221]. The additional safety margin for the </span>
<span id="tk_66" class="t s2_66">planning target volume (PTV) and the planning organ at risk volume (PRV) depends on the type </span>
<span id="tl_66" class="t s2_66">of mask used for immobilization, the patient's </span><span id="tm_66" class="t s3_66">compliance and the type of positioning </span>
<span id="tn_66" class="t s3_66">verification on the linear accelerator. Under optimal conditions, the safety margins can be </span>
<span id="to_66" class="t s3_66">reduced to a minimum of 3 mm from the respective target volume. If daily positioning checks </span>
<span id="tp_66" class="t s3_66">are not carried out, a safety margin of at least 5 mm for the PTV is preferable. In the case of </span>
<span id="tq_66" class="t s3_66">restless patients or if masks do not fit well despite all efforts, safety margins of up to 1 cm for </span>
<span id="tr_66" class="t s3_66">the PTV are necessary. </span>
<span id="ts_66" class="t s3_66">During physical radiation planning, the PTVs should be recorded as conformally as possible </span>
<span id="tt_66" class="t s3_66">with the best possible dose reduction at the PRVs. The recommendations of ICRU 50 and ICRU </span>
<span id="tu_66" class="t s3_66">83 should be taken into account. In the case of carcinomas with prelaryngeal or preepiglottic </span>
<span id="tv_66" class="t s3_66">spread or tumors with a distance of less than 5 millimeters between the tumor tissue and the </span>
<span id="tw_66" class="t s3_66">skin, the use of bolus material (5 mm) is advisable in order to avoid underdosing of tumor </span>
<span id="tx_66" class="t s3_66">tissue due to the "build-up effect" of high-energy photons. The use of IMRT should be preferred </span>
<span id="ty_66" class="t s3_66">in this case (see above). </span>
<span id="tz_66" class="t s4_66">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
